Forgot Password

Thank you for your request!

We will soon reach out to you.

Thank you for downloading..!

Contact us for more information.
Home » Healthcare » Medical Devices » HME-6540817

  • Global Intrauterine Contraceptive Device Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023

  • Publish: July 2017 | Report Code: HME-6540817

* For discount/customization and buying a particular chapter click here or write to us at [email protected]

Intrauterine contraceptive device is a small T-shaped device which is inserted in the uterus of a woman in order to prevent pregnancy. Intrauterine contraceptive devices are a form of long lasting reversible method for birth control. They are 99% effective in preventing unwanted pregnancy, convenient to use, are reversible and starts working immediately after being inserted in the uterus. Due to these advantages, intrauterine contraceptive devices are used by large number of women across the world. Global intrauterine contraceptive device market is expected to rise at a CAGR of 10% during forecast period 2016-2023. Due to increasing number of abortion cases, unplanned pregnancy, reduction of birth control rate has led to increased adoption of intrauterine contraceptive devices. Moreover, there has been an increment in the number of copper intrauterine contraceptive devices users from 0.25% to 0.3% from 2011 to 2016. Furthermore, decrement in the sterilization rates had led to the increase in intrauterine contraceptive devices insertion rates, thereby suggesting that increasing numbers of women adopted for reversible methods of long term contraception instead of permanent sterilization.

Key factors driving the market growth is the increasing prevalence of sexually transmitted diseases. Sexually transmitted diseases have always been a subject for concern due to the unhygienic sexual activities condition and negligence among the people regarding the precautions. According to U.S. based Centres for Disease Control and Prevention, in 2016, large numbers of cases of sexually transmitted diseases such as gonorrhoea, syphilis, chlamydia etc. were recorded in United States. Moreover, untreated sexually transmitted diseases can lead to several health complications such as infertility, sterility, pre-term delivery, genital neoplasia, and foetal/neonatal pathologies. Furthermore, number of cases of syphilis increased to 19% in 2016 thereby causing stillbirths and infant deaths, as reported by public health officials. Also, chlamydia is the most common STD with over 1.5 million cases globally in 2016. According to the 2016 report of World Health Organization, more than 1 million people gets infected by Sexually Transmitted Infections (STIs) every day worldwide. Moreover, sexually transmitted infections like syphilis and herpes can increase the risk of HIV. Therefore, intrauterine contraceptive devices are increasingly adopted to reduce the risks of sexually transmitted diseases and pelvic inflammatory disease. However, intrauterine contraceptive devices do not prevent STD completely, but reduces its risk to a significant extent.

Source: OBRC Analysis.

The report on global intrauterine contraceptive device market includes device type and products.

Types of intrauterine contraceptive device included are:

  • Hormonal intra uterine device
  • Copper intra uterine device



Products of intrauterine contraceptive device included are:

  • Mirena
  • Skyla
  • Paragard
  • Essure
  • Levosert
  • Others







The report scope is widely categorized on the basis of its types which include hormonal intra uterine device and copper intra uterine device.  

Global intrauterine contraceptive device market report has been geographically segmented in:

  • North America (U.S. & Canada)
  • Asia Pacific (China, India, Japan, RoAPAC)
  • Europe (UK, France, Germany, RoE)
  • Rest of World





North America is the largest market region for intrauterine contraceptive device market owing to the increased adoption of these devices in United States. There is high rate of unplanned pregnancies among the teenagers in the U.S. Moreover, the increasing number of initiatives taken by the U.S. government has helped to reduce the rising number of unplanned pregnancies and abortions rate in the United States. Furthermore, many U.S. based private companies have also contributed and provided the solutions for issues during pregnancy which includes teenage pregnancies, maternal mortality, increasing number of abortions etc., by promoting the advantages and use of intrauterine contraceptive devices. Furthermore, Asia Pacific is anticipated to emerge as the fastest growing market region owing to the presence of leading pharmaceutical companies in Asia Pacific countries such as China, Japan, India etc.

Global intrauterine contraceptive device market report covers segmentation analysis of device type and products. Report further covers segments of device type which includes hormonal intra uterine device and copper intra uterine device. Among these segments, copper intra uterine device is the leading segment due to its increased adoption as it is more convenient to use, low threats of side effects, and is considered to be safe for women. Among the females using IUD, 79% of them use copper intra uterine device worldwide. Report further covers segments of products such as Mirena, Skyla, Paragard, Essure, Levosert etc. Mirena is the widely used product thereby accounts for highest market growth. Mirena intrauterine contraceptive device with Progestogen is extensively used to facilitate long time birth control and is 99% effective than any other product.

The major market players of the global intrauterine contraceptive device market are:

  • AGILE THERAPEUTICS
  • ACTAVIS PLC
  • BAYER HEALTHCARE AG
  • TEVA PHARMACEUTICALS INDUSTRIES
  • JOHNSON & JOHNSON
  • OTHERS







These companies using various strategies such as merger & acquisition, collaboration, partnership and product launch. Whereas, product and service launch is the key strategy adopted by the companies in the intrauterine contraceptive device market.

For Example: In September 2016, Bayer Healthcare AG launched its new intrauterine contraceptive device product, named Kyleena intrauterine device for birth control.

In September 2016, Allergan and Medicines 360 announced the launch of their new intrauterine contraceptive device named LILETTA which would prevent pregnancy up to 3 years.

The report covers detailed analysis of companies which comprises overview, SCOT analysis, product portfolio, strategic initiative, strategic analysis, competitive landscape and market share analysis in intrauterine contraceptive device market.

Key reason to buy the report:

  • The report includes market estimation, forecast and analysis for forecast period 2016-2023.
  • Report includes detailed analysis of different segments such as equipment type and applications of intrauterine contraceptive device.
  • Identify and understand the strength, opportunities, challenges and threat of the intrauterine contraceptive device market.
  • Covers details analysis of Porters 5 force model and other strategic models and also covers revenues, market share analysis, and competitive landscape analysis of major players of intrauterine contraceptive device market.
  • Detailed analysis of various the regulatory policies which are affecting the global intrauterine contraceptive device market.






How we are different from others:

At Occams we provide an extensive portfolio which is comprehensive market analysis along with the market size, market share, and market segmentations. Our report on global intrauterine contraceptive device market offers detailed analysis of strategic models such as investment vs. adoption model, see saw analysis and others strategic models. Also, the report contains the detailed analysis of application, adoption scenario and decision support for each segment. The report discusses competitive landscape of the intrauterine contraceptive device market, with giving extensive SCOT analysis of key companies. 

Key findings of the global intrauterine contraceptive device market:

  • The global intrauterine contraceptive device market is expected to rise at a CAGR of 10% during the forecast period 2016-2023.
  • North America is the largest market region for intrauterine contraceptive device market.
  • Copper Intra uterine device is the leading segment due to its increased adoption.
  • Product and service launch is the key strategy adopted by the companies in the intrauterine contraceptive device market.
1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY
 
2. MARKET OVERVIEW
2.1. GLOBAL  INTRAUTERINE CONTRACEPTIVE DEVICE MARKET: EVOLUTION & TRANSITION
2.2. MARKET DEFINITION & SCOPE
2.3. INDUSTRY STRUCTURE
2.4. REGULATORY FRAMEWORK
2.5. TOTAL MARKET ANALYSIS
2.5.1. TOP 5 FINDINGS
2.5.2. TOP 5 OPPORTUNITY MARKETS
2.5.3. TOP 5 COMPANIES
2.5.4. TOP 3 COMPETITIVE STRATEGIES
2.6. ESTIMATION ANALYSIS
2.7. STRATEGIC ANALYSIS
2.7.1. INVESTMENT VS. ADOPTION MODEL
2.7.2. 360-DEGREE INDUSTRY ANALYSIS
2.7.3. PORTERS 5 FORCE MODEL
2.7.4. SEE-SAW ANALYSIS
2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.8. COMPETITIVE ANALYSIS
2.8.1. KEY STRATEGIES & ANALYSIS
2.8.2. MARKET SHARE ANALYSIS AND TOP COMPANY ANALYSIS
2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
 
3. MARKET DETERMINANTS 
3.1. MARKET DRIVERS
3.1.1. TECHNOLOGICAL ADVANCEMENTS IN IUD
3.1.2. INCREASING RATE OF SEXUALLY TRANSMITTED DISEASES
3.1.3. PREGNANCY PREVENTION
3.1.4. IMMEDIATE HEALTH BENEFITS OTHER THAN BIRTH CONTROL
3.1.5. RISE IN GOVERNMENT INITIATIVES TO PREVENT UNWANTED ABORTIONS AND PREGNANCIES
3.2. MARKET RESTRAINTS
3.2.1. LIMITED ACCESS TO CONTRACEPTION
3.2.2. INFERTILITY ISSUES
3.2.3. ECONOMIC CONSTRAINTS
3.3. MARKET OPPORTUNITIES
3.3.1. NEW PRODUCT PIPELINES
3.3.2. SAFEST OPTION AS COMPARED TO OTHER CONTRACEPTIVE PRESENT IN THE MARKET
3.4.  MARKET CHALLENGES 
3.4.1. THREAT OF CAUSING PELVIC INFLAMMATORY INFECTION (PID)
3.4.2. THREAT OF CAUSING ECTOPIC PREGNANCY
 
4. MARKET SEGMENTATION 
4.1. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICE MARKET BY TYPE 
4.1.1. MARKET DEFINITION AND SCOPE
4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.4. OPPORTUNITY MATRIX
4.1.5. MARKET SEGMENTATION 
4.1.5.1. GLOBAL HORMONAL INTRA UTERINE DEVICEMARKET 
4.1.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.1.3. TOP PLAYERS & KEY PRODUCTS 
4.1.5.1.4. KEY CONCLUSIONS
4.1.5.2. GLOBAL COPPER INTRA UTERINE DEVICEMARKET 
4.1.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.2.3. TOP PLAYERS & KEY PRODUCTS 
4.1.5.2.4. KEY CONCLUSIONS
4.2. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICE MARKET BY PRODUCTS
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION 
4.2.5.1. GLOBAL MIRENAMARKET 
4.2.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.1.3. TOP PLAYERS & KEY PRODUCTS 
4.2.5.1.4. KEY CONCLUSIONS
4.2.5.2. GLOBAL SKYLA MARKET 
4.2.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.2.3. TOP PLAYERS & KEY PRODUCTS 
4.2.5.2.4. KEY CONCLUSIONS
4.2.5.3. GLOBAL PARAGARD MARKET 
4.2.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.3.3. TOP PLAYERS & KEY PRODUCTS 
4.2.5.3.4. KEY CONCLUSIONS
4.2.5.4. GLOBAL ESSURE MARKET 
4.2.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.4.3. TOP PLAYERS & KEY PRODUCTS 
4.2.5.4.4. KEY CONCLUSIONS
4.2.5.5. GLOBAL LEVOSERT MARKET 
4.2.5.5.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.5.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.5.3. TOP PLAYERS & KEY PRODUCTS 
4.2.5.5.4. KEY CONCLUSIONS
4.2.5.6. GLOBAL OTHER PRODUCTS MARKET 
4.2.5.6.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.6.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.6.3. TOP PLAYERS & KEY PRODUCTS 
4.2.5.6.4. KEY CONCLUSIONS
 
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF MERGERS AND ACQUISITION
5.1.2. LIST OF JOINT VENTURES
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIPS
 
6. GEOGRAPHICAL ANALYSIS
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICE MARKET BY REGION 2014-2023 ($ MILLION)
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S. 
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.1.3. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.2.3. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.1.3. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.2.3. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.3.3. KEY CONCLUSIONS
6.4.2.2.4. SPAIN
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.4.3. KEY CONCLUSIONS
6.4.2.2.5. REST OF EUROPE
6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.5.3. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.1.3. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.2.3. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.3.3. KEY CONCLUSIONS
6.4.3.2.4. AUSTRALIA
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.4.3. KEY CONCLUSIONS
6.4.3.2.5. REST OF ASIA PACIFIC
6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.5.3. KEY CONCLUSIONS
6.4.4. ROW
6.4.4.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.1.3. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA 
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.2.3. KEY CONCLUSIONS
 
7. COMPANY PROFILES
7.1. AGILE THERAPEUTICS (U.S.)
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. KEY INNOVATION SECTOR
7.1.4. STRATEGIC INITIATIVES 
7.1.5. SCOT ANALYSIS
7.1.6. STRATEGIC ANALYSIS
7.2. ACTAVIS PLC (U.S.)
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. KEY INNOVATION SECTOR
7.2.4. STRATEGIC INITIATIVES 
7.2.5. SCOT ANALYSIS
7.2.6. STRATEGIC ANALYSIS
7.3. BAYER HEALTHCARE AG (U.S.)
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. KEY INNOVATION SECTOR
7.3.4. STRATEGIC INITIATIVES 
7.3.5. SCOT ANALYSIS 
7.3.6. STRATEGIC ANALYSIS
7.4. TEVA PHARMACEUTICALS INDUSTRIES, LTD (ISRAEL)
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. KEY INNOVATION SECTOR
7.4.4. STRATEGIC INITIATIVES 
7.4.5. SCOT ANALYSIS
7.4.6. STRATEGIC ANALYSIS
7.5. JOHNSON & JOHNSON, LTD (U.S.)
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. KEY INNOVATION SECTOR
7.5.4. STRATEGIC INITIATIVES 
7.5.5. SCOT ANALYSIS
7.5.6. STRATEGIC ANALYSIS
7.6. LUPIN PHARMACEUTICALS, LTD (INDIA)
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. KEY INNOVATION SECTOR
7.6.4. STRATEGIC INITIATIVES 
7.6.5. SCOT ANALYSIS 
7.6.6. STRATEGIC ANALYSIS
7.7. OKAMOTO INDUSTRIES, INC. (JAPAN)
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. KEY INNOVATION SECTOR
7.7.4. STRATEGIC INITIATIVES 
7.7.5. SCOT ANALYSIS 
7.7.6. STRATEGIC ANALYSIS
7.8. PFIZER (U.S.)
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. KEY INNOVATION SECTOR
7.8.4. STRATEGIC INITIATIVES 
7.8.5. SCOT ANALYSIS 
7.8.6. STRATEGIC ANALYSIS
7.9. ALLERGAN, PLC (IRELAND)
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. KEY INNOVATION SECTOR
7.9.4. STRATEGIC INITIATIVES 
7.9.5. SCOT ANALYSIS 
7.9.6. STRATEGIC ANALYSIS
7.10. SMB CORPORATION (INDIA)
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. KEY INNOVATION SECTOR
7.10.4. STRATEGIC INITIATIVES 
7.10.5. SCOT ANALYSIS 
7.10.6. STRATEGIC ANALYSIS
7.11. OCON MEDICAL LTD. (ISRAEL)
7.11.1. OVERVIEW
7.11.2. PRODUCT PORTFOLIO
7.11.3. KEY INNOVATION SECTOR
7.11.4. STRATEGIC INITIATIVES 
7.11.5. SCOT ANALYSIS
7.11.6. STRATEGIC ANALYSIS
7.12. MEDISAFE DISTRIBUTION, INC. (CANADA)
7.12.1. OVERVIEW
7.12.2. PRODUCT PORTFOLIO
7.12.3. KEY INNOVATION SECTOR
7.12.4. STRATEGIC INITIATIVES 
7.12.5. SCOT ANALYSIS
7.12.6. STRATEGIC ANALYSIS
7.13. MERIL LIFE SCIENCES PVT. LTD. (INDIA)
7.13.1. OVERVIEW
7.13.2. PRODUCT PORTFOLIO
7.13.3. KEY INNOVATION SECTOR
7.13.4. STRATEGIC INITIATIVES 
7.13.5. SCOT ANALYSIS
7.13.6. STRATEGIC ANALYSIS
7.14. DKT INTERNATIONAL (U.S.)
7.14.1. OVERVIEW
7.14.2. PRODUCT PORTFOLIO
7.14.3. KEY INNOVATION SECTOR
7.14.4. STRATEGIC INITIATIVES 
7.14.5. SCOT ANALYSIS
7.14.6. STRATEGIC ANALYSIS
7.15. TRIMEDIC SUPPLY NETWORK LTD (CANADA)
7.15.1. OVERVIEW
7.15.2. PRODUCT PORTFOLIO
7.15.3. KEY INNOVATION SECTOR
7.15.4. STRATEGIC INITIATIVES 
7.15.5. SCOT ANALYSIS
7.15.6. STRATEGIC ANALYSIS
 
LIST OF TABLES 
 
1. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICE MARKET BY TYPE 2014-2023 ($ MILLION)
2. GLOBAL HORMONAL INTRA UTERINE DEVICE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
3. GLOBAL COPPER INTRA UTERINE DEVICE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
4. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICE MARKET BY PRODUCT 2014-2023 ($ MILLION)
5. GLOBAL MIRENA MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
6. GLOBAL SKYLA MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
7. GLOBAL PARAGARD MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
8. GLOBAL ESSURE MARKET BY GEOGRAPHY  2014-2023 ($ MILLION)
9. GLOBAL LEVOSERT MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
10. GLOBAL OTHER PRODUCTS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
11. NORTH AMERICA INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
12. EUROPE INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
13. ASIA PACIFIC INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
14. REST OF THE WORLD INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
 
 
LIST OF FIGURES
 
1. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
2. GLOBAL HORMONAL INTRA UTERINE DEVICE MARKET 2014-2023 ($ MILLION)
3. GLOBAL COPPER INTRA UTERINE DEVICE MARKET 2014-2023 ($ MILLION)
4. GLOBAL MIRENA MARKET 2014-2023 ($ MILLION)
5. GLOBAL SKYLA MARKET  2014-2023 ($ MILLION)
6. GLOBAL PARAGARD MARKET 2014-2023 ($ MILLION)
7. GLOBAL ESSURE MARKET 2014-2023 ($ MILLION)
8. GLOBAL LEVOSERT MARKET  2014-2023 ($ MILLION)
9. GLOBAL OTHER PRODUCTS MARKET  2014-2023 ($ MILLION)
10. UNITED STATES (U.S.) INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
11. CANADA INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
12. UNITED KINGDOM (UK) INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
13. FRANCE INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
14. GERMANY INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
15. SPAIN INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
16. ROE INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
17. INDIA INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
18. CHINA INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
19. JAPAN INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
20. AUSTRALIA INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
21. ROAPAC INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
22. LATIN AMERICA INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)
23. MENA INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)

FAQ

How can I purchase a report?
We offer an easy way to purchase any report of your choice from various domains that we offer. You can easily search for your desired reports by simply using the search bar on our website's home page. For multiple purchases, you can add reports to the shopping cart, fill a detail form and check out. We accept payments though authentic and trusted payment gateways which accept all major credit cards.
How safe is to use my credit card? Is my information secure?
We ensure complete safety to all online transactions made by credit cards. We use most secure encryption technology available today for the electronic transactions and all our credit card sales are secured with an SSL technology. Your information is highly secure and confidential.
Can I get a discount?
We send discount offers through email as per your request. In case you would like to receive discounts, please sign up for our newsletter.
I want to buy only a chapter. I don't need complete report.
Yes you can buy your desired chapter/page or the entire report, by just clicking on the table of contents in any report and selecting chapter of your interest. We do have separate pricing for chapters/reports/excel sheets/presentation pages etc.
Can I get reports on my desired topic specially which is not available in your current portfolio?
Do call us or mail us the topic of your preference. Our dedicated team on analysts will prepare a report as per your preference and requirements.
When do I get access to the report(s) that I have purchased?
We will email you your purchased report right after we receive your payment through any of the payment options.
Will I receive any invoice for my purchase?
Yes we will email you invoice/payment confirmation with the order details once we receive your payment.
In what format will the reports be available in?
All the reports will be available in PDF format for download.

Request for Sample
Select License Type
Required More Information

0731 4042636

+91 9713031393

NAVIGATION LINK

OUR SERVICES

credit card

CONNECT WITH US

Occams Business Research & Consulting Pvt. Ltd.

Landline: 0731 4042636 

Handheld: +91 9713031393

Email: [email protected]

 

 

  • facebook
  • twitter
  • blog
  • linkdin
  • google plus
  • youtube
Go To Top
viewthroughconversion